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KLF5 (Kru¨ppel-like factor 5) is a zinc-finger transcription factor
that plays a critical role in the regulation of cellular signalling
involved in cell proliferation, differentiation and oncogenesis. In
the present study, we showed that KLF5 acts as a key regulator
controlling the expression of FASN (fatty acid synthase) through
an interaction with SREBP-1 (sterol-regulatory-element-binding
protein-1) in the androgen-dependent LNCaP prostate cancer cell
line. The mRNA level of KLF5 increased when cells were treated
with a synthetic androgen, R1881. Furthermore, KLF5 bound
to SREBP-1 and enhanced the SREBP-1-mediated increase in
FASN promoter activity. The results also demonstrated that the
expression of KLF5 in LNCaP prostate cancer cells enhanced
FASN expression, whereas silencing of KLF5 by small interfering
RNA down-regulated FASN expression. The proximal promoter
region and the first intron of the FASN gene contain multiple
CACCC elements that mediate the transcriptional regulation of
the gene by KLF5. However, other lipogenic and cholestero-
genic genes, such as those encoding acetyl-CoA carboxylase,
ATP-citrate lyase, the LDL (low-density lipoprotein) recep-
tor, HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) synthase and
HMG-CoA reductase are irresponsive to KLF5 expression, owing
to the absence of CACCC elements in their promoter regions.
Taken together, these results suggest that the FASN gene is
activated by the synergistic action of KLF5 and SREBP-1, which
was induced by androgen in androgen-dependent prostate cancer
cells.
Key words: androgen receptor (AR), fatty acid synthase (FASN),
Kru¨ppel-like factor (KLF) family, sterol-regulatory-element-
binding protein-1 (SREBP-1), synergism.
INTRODUCTION
Prostate cancer is the most commonly diagnosed cancer and the
second leading cause of cancer-related deaths among males in
the United States [1]. Androgens have been reported to play a
critical role in the development and maintenance of the prostate, as
well as in the progression of prostate cancer. Therefore androgen
ablation therapy has become the standard modality of treating the
advanced forms of prostate cancer. The AR (androgen receptor),
a member of the nuclear receptor superfamily, is the key player
in this action of androgens [2,3]. Androgens bind and activate the
AR, which acts as a ligand-inducible transcriptional regulator, to
exert their actions on prostate cancer cells.
Several reports have indicated that lipid metabolism is a
major target of androgen action in prostate cancer cells. When
LNCaP cells are exposed to androgens, they induce a massive
accumulation of neutral lipids, which are storage products of
fatty acid and cholesterol [4]. Increased synthesis of fatty acids
and cholesterol by androgens is mediated by stimulation of
the expression of whole sets of lipogenic enzymes, covering
the entire pathway of fatty acid and cholesterol synthesis [5].
Up-regulation of FASN (fatty acid synthase) mRNA and FASN
protein is one of the earliest and most common events in the
development of prostate cancer, and a strong association between
FASN expression and tumour progression has been shown [5,6].
Accordingly, the level of FASN is much higher in tumours with
significantly high Gleason scores than demonstrated for benign
prostate hyperplasia [7].
FASN, a 250–270 kDa cytosolic protein, is an enzyme that
catalyses de novo fatty acid synthesis in the cell. In normal
human tissues, endogenous fatty acid synthesis is maintained at
a minimum, since the exogenous influx of fatty acids meets most
of the cellular requirements for fatty acids. However, FASN is
overexpressed in various human malignancies, including prostate,
breast, ovarian, endometrial, colorectal, lung, stomach and skin
cancers [5,8–15]. Treatment of tumour cells with pharmacological
inhibitors of FASN leads to apoptosis and cell-cycle arrest
[16]. These observations support the hypothesis that FASN over-
expression confers a selective advantage to tumour cells by
inhibiting apoptosis and promoting cell-cycle progression.
Therefore FASN has become an important target for the potential
diagnosis and treatment of cancers. However, relatively little is
known about the mechanism controlling the expression of the
FASN gene in human tumours.
The genes encoding the enzymes involved in fatty acid meta-
bolism are SREBPs (sterol-regulatory-element-binding proteins)
[17,18]. SREBPs are a family of basic helix-loop-helix leucine-
zipper transcription factors that are synthesized as inactive
precursor proteins anchored to the ER (endoplasmic reticulum)
membrane [18]. There they interact with an SCAP (SREBP
cleavage-activating protein), which is retained in the ER by Insig
retention proteins [19]. The SCAP–SREBP–Insig complex is
stabilized by cholesterol. When sterol levels are low, the SCAP–
SREBP complex is released from Insigs and moves to the Golgi,
where the N-terminus of SREBP is released by a two-step
proteolysis reaction resulting in its translocation to the nucleus.
Abbreviations used: ACACA, acetyl-CoA carboxylase α; ACLY, ATP citrate lyase; AR, androgen receptor; DTT, dithiothreitol; ER, endoplasmic reticulum;
FASN, fatty acid synthase; FBS, fetal bovine serum; CT-FBS, dextran-coated charcoal-treated FBS; HA, haemagglutinin; HMG-CoA, 3-hydroxy-3-
methylglutaryl-CoA; HMGCS1, HMG-CoA synthase 1; HRP, horseradish peroxidase; KLF, Kru¨ppel-like factor; LDL, low-density lipoprotein; LDLR, LDL
receptor; PI, promoter I; PII, promoter II; RT-PCR, real-time PCR; siRNA, small interfering RNA; SRE, sterol-response element; SREBP, sterol-regulatory-
element-binding protein; SCAP, SREBP cleavage-activating protein; Sp, stimulating protein; Sp/KLF, Sp1-like protein and KLF.
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This transcriptionally active fragment activates the transcription
of multiple genes involved in the synthesis, binding, metabolism
and uptake of fatty acids and cholesterol by binding to the SRE
(sterol-response element) [18].
SREBP-dependent transcriptional regulation of several pro-
moters is dependent on the presence of additional binding sites
for ubiquitous transcription factors. In the promoter regions of
ACACA (acetyl-CoA carboxylase α), LDLR [LDL (low-density
lipoprotein) receptor] and FASN genes, which are targets of
SREBP, the binding site for the transcription factor Sp (stimu-
lating protein) 1 plays a critical role in SREBP-mediated
transcriptional regulation [20].
KLFs (Kru¨ppel-like factors) have been reported previously
to be important components of the eukaryotic transcriptional
machinery [21]. The Sp/KLF (Sp1-like protein and KLF) family
is composed of at least two highly related zinc-finger proteins,
of which the DNA-binding domains are conserved at the C-
termini with three tandem Cys2His2 zinc-finger motifs [22].
These conserved motifs can bind to DNA as well as functioning
in protein–protein interactions [23,24]. Sp/KLF proteins can
function as either activators or repressors, depending on the
promoters that they bind [23,25,26]. Since many Sp1/KLF
proteins regulate cell growth in a variety of ways in different cell
types, it is not surprising that some members of the family also
appear to participate in carcinogenesis. KLF5 has been reported
to encode a delayed early response gene product that positively
regulates cellular proliferation [27] and plays an oncogenic role
in human bladder cancer cells through the regulation of a subset
of genes [28].
In the present study, we demonstrate that KLF5 can activate
the transcription of the FASN gene through its synergistic action
with SREBP-1 in androgen-dependent LNCaP prostate cancer
cells. The expression of KLF5 was consistently associated with
high levels of FASN expression in these cells. Analyses of the
FASN promoter showed that KLF5 functions as a stimulator
of FASN transcription in co-ordination with SREBP-1. Our
findings suggest that KLF5 may be a novel target for anticancer
therapy by modulating the expression of FASN with resulting
changes in lipid metabolism in cancer cells.
MATERIALS AND METHODS
Cell culture
The human prostatic adenocarcinoma cell line LNCaP was
obtained from the A.T.C.C., and the PC3 cell line was provided
by Dr Joohun Ha (Department of Biochemistry and Molecular
Biology, Kyung Hee University School of Medicine, Seoul,
Republic of Korea). Cells were maintained at 37 ◦C in a
humidified atmosphere of 5% CO2/95% air in RPMI 1640
medium (Invitrogen) supplemented with a reduced level of
sodium bicarbonate (1.5 g/l), 10% (v/v) FBS (fetal bovine
serum), 100 μg/ml streptomycin and 100 units/ml penicillin.
When appropriate, CT-FBS (dextran-coated charcoal-treated
FBS) [29] was used instead of FBS to minimize the concentration
of steroids in the culture medium. The synthetic androgen R1881
(DuPont/New England Nuclear) was prepared in absolute ethanol
and added to the culture medium to a final concentration of less
than 0.1%.
Promoter reporter constructs and transient transfection assay
The promoters for ACACA [PI (promoter I) and PII (promoter II)],
ACLY (ATP citrate lyase) and FASN were amplified by PCR using
genomic DNA prepared from LNCaP cells. PCR was performed
using the following primers: ACACA-PI sense, 5′-CACGAGAA-
TCGCTCGAGCCTGGGAG-3′ and antisense, 5′-TCCTCCCA-
GTCCTCGAGCACGGGGA; ACACA-PII sense, 5′-TGGAA-
CGCTGTGGCAACTATTTTGC-3′ and antisense, 5′-AGTTT-
CTCCAGGTCCCCGGTCACAG-3′; ACLY sense, 5′-GGGTA-
CTCCAGGTCCCAAAGCTGCG-3′ and antisense, 5′-GAAC-
CCCGCAAAATCCGGAGCACCC-3′; and FASN sense, 5′-AC-
ACGAACACAATGCTCTGC-3′ and antisense, 5′-TG-
AGGTTGTCCCAGAACTCC-3′. For ACACA-PI, XhoI and
BglII restriction sites were introduced using the sense and
antisense primers respectively. The amplified PCR fragment
of ACACA-PI was digested with XhoI and BglII and then
inserted into the same restriction sites in the pGL3-basic vector
(Promega). The amplified PCR fragments for ACACA-PII, ACLY
and FASN were inserted into the SmaI site of the pGL3-basic
vector by bluntend ligation. PCR was performed using LA
Taq polymerase in 2× GC buffer II (TaKaRa) following
the manufacturer’s instructions. The HMGCS1 [HMG-CoA
(3-hydroxy-3-methylglutaryl-CoA) synthase 1] promoter
construct [17] was provided by Dr Johannes V. Swinnen
(Department of Experimental Medicine and Endocrinology,
Katholieke Universiteit Leuven, Leuven, Belgium).
For androgen-dependent transcriptional activation assays of the
promoter constructs, LNCaP cells were cultured at a density
of 4 × 106 cells/100-mm-diameter dish in RPMI 1640 medium
containing 5% (v/v) CT-FBS. After 2 days, cells were transfected
with the indicated luciferase reporter plasmids (3 μg) using
LipofectamineTM and Plus Reagent (Invitrogen) following the
manufacturer’s instructions. After 6 h of incubation, the cell
medium was exchanged for fresh RPMI 1640 medium containing
5% (v/v) CT-FBS. To ensure the same transfection efficiency
for each treatment group, cells were trypsinized and equal
numbers of transfected cells were seeded in six-well dishes
18 h after transfection in the presence or absence of 10 nM
R1881. After 72 h of incubation, cells were washed with PBS
and harvested in 200 μl of reporter lysis buffer (Promega). The
cells were mixed vigorously for 15 s and centrifuged at 12000 g
for 10 min at 4 ◦C. The supernatants were transferred into a fresh
tube, and 5 μl aliquots of the cleared whole-cell lysate were
assayed for luciferase activity using a Luciferase Reporter Assay
kit (Promega). Each transfection experiment was performed in
triplicate, and the luciferase activity was normalized to the amount
of protein present in the lysate.
The eukaryotic expression plasmids encoding full-length
KLF4, KLF5 or SREBP1c were constructed by PCR using cDNAs
synthesized from the total RNA from LNCaP cells. The amplified
PCR fragments were cloned into the pSG5-HA (haemagglutinin)-
tagged expression vector by blunt-end ligation.
Western blot analysis
Cells were lysed in a buffer containing 25 mM Hepes (pH 7.6),
1.1 M urea, 0.33 M NaCl, 1% Nonidet P40, 1 mM PMSF, 1 mM
DTT (dithiothreitol) and 1 mM sodium orthovanadate. Lysates
were briefly vortexed and cleared by centrifugation at 12000 g
for 10 min at 4 ◦C. The supernatants were collected and protein
concentrations were determined using a Bradford assay kit (Bio-
Rad). Aliquots of protein (20 μg) were subjected to SDS/PAGE
[5% (for ACACA, ACLY and FASN) or 8% gels (for all
other proteins)] and transferred on to nitrocellulose membranes
(Schleicher and Schuell). Western blot analyses were performed
using the following antibodies: rabbit polyclonal antibodies
against ACACA (1:5000 dilution), ACLY (1:5000 dilution),
FASN (1:5000 dilution), SREBP-1 (1:2500 dilution), SREBP-2
(1:2500 dilution), HMGCS1 (1:2000 dilution) and SCAP
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(1:2500 dilution) (Genepia), mouse monoclonal anti-HA
antibody (1:2000 dilution; Santa Cruz Biotechnology), mouse
monoclonal anti-FLAG antibody (1:5000 dilution; Sigma), and
mouse monoclonal anti-α-tubulin antibody (1:2500 dilution;
Calbiochem). The immunoreactive signals were visualized using
an HRP (horseradish peroxidase)-conjugated goat anti-(rabbit
IgG) antibody (1:5000 dilution) or HRP-conjugated goat anti-
(mouse IgG) antibody (1:5000 dilution) (Pierce) using the
SuperSignal West Pico Chemiluminescent Substrate System
(Pierce) following the manufacturer’s instructions.
RNA isolation and RT-PCR (real-time PCR)
Total RNA was isolated from cultured cells using TRIzol®
(Invitrogen) according to the manufacturer’s instructions. For
quantitative RT-PCR, cDNAs were synthesized from 5 μg of
total RNA using random hexamer primers and SuperScript
reverse transcriptase II (Invitrogen) following the manufacturer’s
instructions. An aliquot (1/50) of the reaction was used for
quantitative PCR using the SYBR Green PCR Master Mix
(Applied Biosystems) and gene-specific primers, and this was
then subjected to RT-PCR quantification using the ABI PRISM
7300 RT-PCR System (Applied Biosystems). The sequences
of the primers used for RT-PCR are listed in Supplementary
Table S1 (http://www.BiochemJ.org/bj/417/bj4170313add.htm).
All reactions were performed in triplicate. The relative amounts
of the mRNAs were calculated using the comparative cycle-time
method [Applied Biosystems User Bulletin number 2 (2001);
Applied Biosystems]. GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) mRNA was also measured as an invariant control.
RNA interference
Two siRNAs (small interfering RNAs) were designed to target
KLF4 and KLF5 mRNA with the target sequences 5′-GACCG-
AGGAGTTCAACGATUU-3′ and 5′-AAAGTATAGACGAGAC-
AGTGCUU-3′ respectively. A scrambled control siRNA
(siCONTROL; Dharmacon) was used as a transfection control.
For siRNA transfection, cells were seeded in 100-mm-diameter
dishes or in 12-well plates at a density of 3 × 106 cells/dish
in 5% (v/v) CT-FBS-supplemented RPMI 1640 medium
without antibiotics and cultured for 48 h. The transfection was
performed three times over 3 days with 200 nM chemically
synthesized siRNAs using LipofectamineTM RNAiMAX (Invitro-
gen) following the manufacturer’s protocol. Briefly, the medium
was changed to RPMI 1640 medium containing 1% CT-FBS
in the presence of 10 nM R1881. The siRNA solution was then
mixed with LipofectamineTM RNAiMAX in OptiMEM I medium
for 20 min before being added to the cultured cells. Total RNA
or protein extracts were prepared from the cells 72 h after the
first transfection, and RT-PCR and immunoblot analyses were
performed.
Immunoprecipitation
Cells were lysed in a buffer composed of 50 mM Tris/HCl
(pH 7.4), 150 mM NaCl, 0.3% Nonidet P40, 0.2% Triton X-
100, 1 mM sodium orthovanadate, 1 mM PMSF, 1 mM DTT
and protease inhibitors (Sigma) and, after centrifugation, 500 μg
of the clarified cell lysate was pre-cleared by incubating for
2 h at 4 ◦C with 50 μl of a 50% (v/v) Protein A/G Plus–agarose
slurry (Santa Cruz Biotechnology). An anti-FLAG antibody
(2 μg) was incubated with the pre-cleared cell lysate overnight
at 4 ◦C. After incubation, 50 μl of Protein A/G Plus–agarose was
added and incubated for 2 h at 4 ◦C. The agarose was centrifuged,
washed three times with ice-cold PBS, resuspended in SDS/PAGE
sample buffer and boiled for 3 min. The immunoprecipitate was
Figure 1 Androgen-dependent regulation of lipogenic gene expression in
LNCaP prostate cancer cells
LNCaP cells were incubated for 3 days in the absence (Control) or presence of 10 nM R1881
in 1 % CT-FBS medium, which was used to optimize the androgen effect. (A) Total RNA was
isolated and subjected to RT-PCR with primers for lipogenic and cholesterogenic enzymes as
described in Supplementary Table S1 (http://www.BiochemJ.org/bj/417/bj4170313add.htm).
The values indicates the fold change between samples of control and R1881-treated mRNAs.
Results are means +− S.D. (n = 3) with each experiment performed in triplicate. (B) Whole-cell
lysate (20 μg) was resolved by SDS/PAGE and immunoblotted for each of the proteins indicated,
with α-tubulin (Tubulin) detected as an internal loading control. HMGCR, HMG-CoA reductase;
PSA, prostate-specific antigen.
then analysed by SDS/PAGE and Western blotting as described
above.
Microarray analysis
Total RNA from LNCaP cells was prepared using TRIzol®
(Invitrogen), which were grown in RMPI 1640 medium
supplemented with 1% CT-FBS in the absence or presence
of 10 nM R1881 for 3 days. The microarray hybridization
was carried out by GenoCheck using a human whole 35000
oligonucleotide chip provided by Operon.
RESULTS
Androgen up-regulates the expression of lipogenic enzymes and
SREBPs are involved in this regulation
To determine whether androgen modulates the expression of
lipogenic genes in prostate cancer cell lines, LNCaP cells
were cultured for 3 days in the absence or presence of 10 nM
R1881. After incubation, the expression levels of lipogenic or
cholesterogenic enzymes were analysed by immunoblot analyses
and RT-PCR. As shown in Figure 1(A), the amount of mRNAs of
the genes encoding these enzymes was up-regulated by androgen,
and the increase in the level of FASN mRNA was the most
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Figure 2 SREBPs are involved in androgen-dependent regulation of lipogenic gene expression
LNCaP cells were incubated in 5 % (v/v) CT-FBS-containing medium for 48 h and then transfected with wild-type (WT) or mutant SRE (mSRE) reporter constructs (0.5 μg/μl) containing FASN
(A) and HMGCS1 (B) promoters. Constructs were incubated for 72 h in the absence (Control) or presence of 10 nM R1881 in 1 % CT-FBS-containing medium, and luciferase activities were
measured. The relative luciferase activity was converted into the fold increase in activity (values shown above bars). Results are means +− S.D. (n = 3) with each experiment performed in triplicate.
(C) Total RNA and protein were isolated from LNCaP cells 3 days after incubation in 1 % CT-FBS medium in the absence (Control) or presence of 10 nM R1881 and were subjected to RT-PCR and
immunoblotting to determine the levels of SREBP-1, SREBP-2 and SCAP mRNA and protein respectively. Tubulin was used as an internal loading control. Values shown above bars indicate the fold
increase in relative mRNA levels. Results are means +− S.D. (n = 3) with each experiment performed in triplicate. Ex, exon; Luc, luciferase; M, mature; NF-Y, nuclear factor-Y; P, premature.
prominent. The mRNA level of the KLK3 gene [the gene encoding
PSA (prostate-specific antigen)] which is known to be a direct
target of the AR, was markedly elevated by androgen. Increases
in the amounts of these proteins by androgen were verified by
immunoblot analyses with available antibodies (Figure 1B).
Since SREBPs are well known principal transcriptional
regulators of the expression of lipogenic or cholesterogenic
enzymes, we determined the changes in the expression of SREBPs
and SCAP in LNCaP cells after androgen treatment. In LNCaP
cells, androgen is known to induce the expression of SCAP,
resulting in an increase in the processing of SREBP precursors into
mature forms [17]. To confirm whether SREBPs play an important
role in androgen-dependent activation of lipogenic and chol-
esterogenic genes, we performed transient transfection assays
using the reporter constructs harbouring promoters for FASN and
HMGCS1 (Figures 2A and 2B). The critical SREs for SREBP-
mediated transactivation have been characterized precisely in the
promoters of FASN [31] and HMGCS1 [32]. These promoters
were drastically activated by androgen treatment, and mutation
of the SREs almost completely abolished androgen-dependent
activation. These results indicate that the activity of SREBPs plays
a critical role in androgen-dependent increases in lipogenic and
cholesterogenic gene expression. The transcripts for SCAP,
SREBP-1 and SREBP-2 were minimally increased. The increase
in the level of the mature forms of SREBP and SCAP proteins
as a result of androgen was not drastic, although the amount
of the premature forms of SREBPs detected was up-regulated
(Figure 2C).
To evaluate the actions of androgen, free steroids in the
serum were removed by the addition of CT-FBS, and 1% CT-
FBS was used instead of 10% FBS in culture medium. The
charcoal treatment does not remove cholesterol in lipoproteins,
but depletion of the serum in the medium might significantly
reduce cholesterol levels, resulting in a possible induction of
processing of SREBPs. To rule out this possibility, the expression
levels of SREBPs were verified in cells incubated in medium
containing 10% (v/v) FBS or 1% CT-FBS. The low levels of
cholesterol in the 1%CT-FBS-containing medium were probably
not low enough to change the processing of SREBPs, because
no changes in the levels of the premature and mature forms
of SREBPs were detected in 1%CT-FBS medium compared with
SREBPs incubated in 10% (v/v) FBS (results not shown). These
observations excluded the possibility that enhanced expression of
SREBPs by serum depletion could mask the effects of androgen
on SREBP activation. In summary, it suggests the possibility that
the existence of other transcription factors affected by androgen
treatment might regulate the transactivation activities of SREBPs.
KLF5 level is increased by androgen in LNCaP prostate cancer
cells and is associated with the expression of the FASN gene
In many promoters, the transactivation functions of SREBPs
work efficiently in synergy with different ubiquitous transcription
factors, such as Sp1 and NF-Y (nuclear factor-Y) [20,33–36]. In
previous studies, Sp1 was reported to be required for SREBP-
mediated activation of the FASN, ACACA, ACACB (acetyl-CoA
carboxylase β) and LDLR genes [20,34]. However, the DNA-
binding activity and protein levels of Sp1 were not changed by
androgen (results not shown). Microarray analysis provided the
information that KLF4 and KLF5, which belong to the Sp/KLF
family, were induced by androgen. RT-PCR showed that the
transcripts of KLF4 and KLF5 were significantly increased by
androgen up to 5.5- and 3.3-fold respectively (Figure 3).
To confirm further the association between KLF5 and lipogenic
enzymes in prostate cancer cells, KLF5 was overexpressed
to see whether forced expression of KLF5 could affect the
activities of the promoters for various lipogenic genes. Only
the FASN promoter showed significantly increased activity in
c© The Authors Journal compilation c© 2009 Biochemical Society
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Figure 3 mRNA levels of KLF4 and KLF5 are increased by androgen
treatment in LNCaP prostate cancer cells
LNCaP cells were seeded in an 100-mm-diameter dish and incubated in 5 % (v/v)
CT-FBS-containing medium. The cells were incubated for 3 days in the absence (Control)
or presence of 10 nM R1881 in 1 % CT-FBS-containing medium. Total RNA was prepared
and subjected to RT-PCR with KLF4 and KLF5 primers [detailed in Supplementary Table S1
(http://www.BiochemJ.org/bj/417/bj4170313add.htm)]. The relative amount of mRNA was
converted into the fold increase in relative mRNA levels (values shown above bars). Results are
means +− S.D. (n = 3) with each experiment performed in triplicate.
response to KLF5 overexpression (Figure 4A). Comparisons
between the FASN promoter and other lipogenic promoters
explain that multiple CACCC elements for KLF binding are
scattered throughout the upstream sequences and the first intron of
the FASN gene, whereas these elements are scarce in the ACACA-
PI, ACACA-PII, ACLY and HMGCS1 promoters (Figure 4B).
Since KLF4, which recognizes the same CACCC elements
as KLF5, was also increased by androgen, forced expression
of KLF4 was performed to test whether similar results were
produced. The promoter activity of FASN did not show any
response to KLF4 overexpression (see Figure 6B). Consequently,
KLF5, but not KLF4, increases the promoter activity of FASN
when overexpressed in LNCaP cells.
KLF5 interacts with SREBP in regulating FASN expression
The next step was to determine the role of KLF5 in SREBP-1-
mediated activation of the FASN promoter. The overexpression
plasmids for SREBP-1c and/or KLF5 were transfected in
tandem with the FASN promoter construct into PC3 prostate
cancer cells. The promoter activity was increased by KLF5 and
SREBP-1c overexpression up to 14- and 27-fold respectively
(Figure 5A). Moreover, the activity was dramatically increased
to more than the additive value when SREBP-1c and KLF5
were overexpressed together. On the other hand, the SRE mutant
construct almost completely abolished SREBP-1c-mediated
activation and the synergy between KLF5 and SREBP-1c without
affecting responsiveness to KLF5.
To confirm further the synergistic effect of KLF5 and SREBP-
1c, the induction of FASN promoter activity was measured
when the concentration of SREBP-1c was changed in the
absence or presence of KLF5 overexpression. When KLF5 was
overexpressed, the FASN promoter sensitively and drastically
responded to SREBP-1 in a dose-dependent manner, whereas its
activation by SREBP-1c alone was low in the absence of KLF5
overexpression (Figure 5B). As a result, SREBP-1-mediated
activation of the FASN promoter is enhanced by the addition of
KLF5.
Next, protein–protein interactions were examined, since KLF5
and SREBP-1 were shown above to act in co-operation. HA-
tagged SREBP-1 and/or FLAG-tagged KLF5 constructs were
transfected into PC3 cells and incubated for 48 h. Cells were then
Figure 4 KLF5 regulates wild-type FASN promoter activity in LNCaP
prostate cancer cells
(A) Control and lipogenic promoter constructs (0.1 μg/μl) were co-transfected with control
(pSG5) (−) or the KLF5 expression vector (hKLF5-pSG5) (+) (0.9 μg/μl) into LNCaP cells.
After 2 days, transfected cells were lysed and their luciferase activities were measured. The
relative luciferase activity was converted into the fold increase in activity (values shown above
bars) (upper panel). Results are means +− S.D. (n = 3) with each experiment performed in
triplicate. The samples were then subjected to immunoblotting to confirm whether KLF5 proteins
were expressed (lower panel). (B) Structures of ACACA-PI, ACACA-PII, ACLY , HMGCS1 and
FASN-WT lipogenic promoter constructs used in (A), with the lengths of their promoter regions
indicated. Black vertical bars represents CACCC elements. Ex, exon; FASN-WT, wild-type FASN;
Luc, luciferase.
harvested, the total-cell lysate was immunoprecipitated using an
anti-FLAG antibody and then HA-tagged SREBP-1 was detected
in the immunoprecipitates. SREBP-1 was markedly increased
when FLAG-tagged KLF5 was expressed (Figure 5C, lane 4),
indicating that SREBP-1 and KLF5 physically interact with each
other (Figure 5C).
To elucidate the correlation between KLF5 and FASN
expression in LNCaP cells, the cell line was transfected with the
KLF5 expression plasmid and the endogenous level of FASN was
measured. When the cells were transfected with empty vector, the
endogenous level of FASN was low (Figure 5D). Nonetheless,
when the exogenous KLF5 expression vector was introduced by
transfection, the endogenous level of FASN protein increased
significantly. In the case of other lipogenic enzymes, such as
ACACA, ACLY and HMGCS1, the expression levels were not
changed at all by KLF5 overexpression.
KLF5 drastically enhances androgen-dependent activation
of the FASN promoter
The activity of the FASN promoter can be activated markedly
by a synergistic action between exogenously expressed KLF5
and SREBP-1. However, if SREBP-1 is activated by androgen
c© The Authors Journal compilation c© 2009 Biochemical Society
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Figure 5 Co-operative action and physical interaction between SREBP and KLF5 in regulating FASN transcription
(A) The wild-type FASN (WT-FASN) and the mutant SRE FASN (FASN-mSRE) reporter constructs (0.1 μg/μl) were co-transfected with an empty vector (control; pSG5), SREBP1c (SREBP1c-pSG5)
(0.45 μg/μl), KLF5 (KLF5-pSG5) (0.45 μg/μl), or both KLF5 and SREBP1c (KLF5 + SREBP1c) in PC3 cells, and the promoter activities were measured. The relative luciferase activity was converted
into fold increase in luciferase activity (values indicated above bars). Results are means +− S.D. (n = 3) with each experiment performed in triplicate. (B) The wild-type FASN (WT-FASN) promoter
construct (0.1 μg/μl) was co-transfected with control (, pSG5) or KLF5 (, hKFL5-pSG5) (0.1 μg/μl), and various concentrations of the SREBP-1c expression plasmid in LNCaP cells seeded
in six-well plates. The relative luciferase activities were measured after 48 h of incubation and the luciferase activity was normalized to the amounts of protein present in the lysate. Results are
means +− S.D. (n = 2) with each transfection performed in triplicate. (C) PC3 cells were seeded in a 100-mm-diameter dish and transfected with HA-tagged SREBP-1c (3 μg/μl) (SREBP1c-HA),
FLAG-tagged KLF5 (3 μg/μl) (KLF5-FLAG) or both (KLF5-FLAG + SREBP1c-HA). After 2 days, cells were lysed and subjected to immunoprecipitation (IP). The pre-cleared cell lysate (500 μg)
was incubated with 2 μg of anti-FLAG antibody overnight at 4◦C. The following day, 50 μl of Protein A/G Plus–agarose was added and incubated for 2 h. The agarose was centrifuged, washed and
resuspended in SDS/PAGE sample buffer (see the Materials and methods section for details). The immunoprecipitated protein was analysed by immunoblotting (IB) using an anti-HA antibody,
and cell lysates (Input) were immunoblotted using anti-HA and anti-FLAG antibodies. (D) A control plasmid (−) or KLF5 expression plasmid (+) (FLAG-KLF5) (5 μg/μl) was transfected into
LNCaP cells seeded in a 100-mm-diameter dish, and cells were lysed 48 h after transfection. Total protein was then prepared for immunoblotting with the indicated antibodies, with tubulin used as
an internal loading control.
in LNCaP cells, exogenous KLF5 could enhance the androgen-
dependent activation of the FASN promoter. Therefore the
androgen-dependent activity of the FASN promoter was measured
in the absence or presence of KLF5. The promoter activity
of FASN was increased to 68- and 34-fold by androgen
treatment and KLF5 overexpression respectively (Figure 6A).
Furthermore, the activity markedly increased to 545-fold when
androgen treatment was added in the presence of KLF5 over-
expression.
Next, the promoter activity of FASN was measured using the
KLF4 expression plasmid instead of KLF5. Contrary to the pre-
vious result, the increased promoter activity of FASN by
androgen did not have any synergistic action when KLF4 was
overexpressed (Figure 6B). In order to determine whether the
synergistic activation between KLF5 and androgen occurs in
other SREBP-controlled promoters, we measured the effect
of KLF5 on HMGCS1 promoter activity in androgen-treated
LNCaP cells. As shown previously, the HMGCS1 promoter
responded to androgen treatment effectively, but not to KLF5
expression (Figure 6C). KLF5 slightly increased the activity of the
HMGCS1 promoter by androgen, but the increased amount was
small when compared with the increase in the FASN promoter
induced by KLF5. These results demonstrate that KLF5 could
specifically reinforce the androgen-dependent activation of the
FASN promoter, which makes FASN unique among lipogenic
genes.
KLF5 siRNA suppresses androgen-mediated FASN expression
FASN expression is most prominently activated by androgen in
LNCaP cells, and SREBP-1 plays a critical role in this induction.
However, a dramatic change in the level of the mature form of
SREBP-1 after androgen treatment was not detected. The fact
that KLF5 is increased, even by a small amount, by androgen
and synergistic action with SREBP, suggested the possibility that
KLF5 could also play a critical role in FASN induction. On the
basis of this hypothesis, knockdown of KLF5 was performed
to test whether FASN induction was blocked by androgen in
LNCaP cells. A specific KLF5 siRNA, which was synthesized
as described previously [37], decreased the mRNA level of KLF5
to 80% compared with treatment with control siRNA, which did
not markedly decrease KLF5 mRNA levels (Figure 7A). However,
even this small knockdown of KLF5 expression significantly
increased KLF4 expression. The increase in the level of KLF4 by
KLF5 siRNA might be explained by a previous report in which
KLF4 transcription was demonstrated to be strongly suppressed
by KLF5, and as a result, repression by KLF5 knockdown is
sufficient to induce physiological changes [38]. The mRNA level
c© The Authors Journal compilation c© 2009 Biochemical Society
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Figure 6 Effect on wild-type FASN promoter by SREBP, KLF5 and AR
Wild-type FASN (FASN-WT) or FASN-mSRE (mutant SRE) constructs (0.1 μg/μl) were
co-transfected with control plasmid (pSG5), KLF5 plasmid (KLF5-pSG5) (A) or KLF4 plasmid
(KLF4-pSG5) (B) (0.9 μg/μl). The following day, cells were changed to 1 % CT-FBS-containing
medium in the absence or presence (+) of R1881, and incubated for a further 3 days. Cells were
harvested and the relative luciferase activity was measured and is expressed as the fold increase
(values shown above bars). (C) The HMGCS1 promoter (0.1 μg/μl) was co-transfected with
control (pSG5) or KLF5 plasmid (0.9 μg/μl) (KLF5-pSG5) and treated as stated in (A and
B). Cells were harvested and the relative luciferase activity was measured and is expressed as
the fold increase (values shown above bars). All results are means +− S.D. (n = 3) with each
experiment performed in triplicate.
of FASN was effectively suppressed by KLF5 siRNA to 40%
of that of the control siRNA group, whereas the mRNA levels
of ACACA, ACLY and HMGCS1 were not significantly affected.
Moreover, the protein level of FASN was decreased notably after
treatment of cells with KLF5 siRNA, whereas the protein level of
HMGCS1 was not affected (Figure 7B). Since the mRNA level of
KLF4 was increased by androgen and it binds to the same CACCC
element as KLF5, the expression level of FASN was also tested
in KLF4 siRNA-treated cells [39]. Transfection of KLF4 siRNA
neither reduced the protein level of FASN nor HMGCS1. These
results indicate that KLF5 is involved in androgen-dependent
expression of FASN in LNCaP cells, but KLF4 is not involved.
CACCC elements are scattered in the FASN promoter and intron 1,
which makes KLF5 a positive regulator
The FASN promoter, which shows responsiveness to KLF5,
contains multiple CACCC elements for KLF5 binding. To
discriminate which CACCC elements play a critical role in
the responsiveness to KLF5, serial deletion constructs of the
FASN promoter were generated as shown in Figure 8(A), and
a transient transfection assay was performed in PC3 prostate
cancer cells overexpressing KLF5 (Figure 8B). When KLF5
was overexpressed, the promoter activity of the pLuc-(2.7 kb)
construct increased by 58-fold. Moreover, pLuc-(1.0 kb) and
pLuc-(0.4 kb) plasmids were increased 42.1- and 39.7-fold by
Figure 7 Effect on KLF5 or KLF4 siRNA on the expression levels of
endogenous KLF5, KLF4 and lipogenic genes
LNCaP cells were seeded in 5 % (v/v) CT-FBS medium without antibiotics and incubated for
48 h. The cells were transfected with 200 nM control siRNA (siCON/Con), KLF5 siRNA (siKLF5)
or KLF4 siRNA using LipofectamineTM RNAiMAX three times over 3 days in 1 % CT-FBS medium
in the presence of 10 nM R1881. Total RNA (A) or protein (B) was collected 3 days after the first
transfection, and RT-PCR (A) and immunoblotting (B) was performed as indicated. For RT-PCR,
the fold increase in mRNA is shown (values shown above bars) and results are means +− S.D.
(n = 2), with each experiment performed in triplicate. For immunoblotting, detection ofα-tubulin
(Tubulin) was used as an internal loading control.
KLF5 overexpression respectively. To test the contribution of
intron sequences for the responsiveness to KLF5, the intron region
was deleted from the construct (intron constructs). The basal
activity was greatly increased by deletion of the intron, but the
responsiveness to KLF5 was still present. This result indicates that
the first intron strongly suppressed FASN promoter activity and
suggests the possibility that KLF5 binding to multiple CACCC
elements in the first intron might play a significant role in ablating
the suppressive activity residing in the first intron. Furthermore,
CACCC elements within the pLuc-(0.4 kb) promoter region might
play a critical role in activating the FASN promoter, since the pro-
moter activity was still present despite complete deletion of the
first intron. Consequently, the scattered multiple KLF5-binding
c© The Authors Journal compilation c© 2009 Biochemical Society
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Figure 8 Deletion and mutation analysis of FASN promoter activity
(A) Structures of deletion and mutation FASN promoter constructs. The numbers in parentheses
represent the length of each promoter. (B) Transient transfection and luciferase assay was
performed in PC3 cells. FASN promoter constructs [0.1 μg/μl, see (A) for details] were
co-transfected with either KLF5 (hKLF5-pSG5) or control (pSG5) (0.9 μg/μl) plasmids. At
48 h, cell extracts were analysed for luciferase activity. Fold increase in luciferase activity is
also shown (values shown above bars). Results are means +− S.D. (n = 3) with each experiment
performed in triplicate. Ex, exon; Luc, luciferase.
sites around the proximal promoter region and the first intron can
activate the FASN promoter.
DISCUSSION
The present study demonstrates that KLF5 is expressed in
LNCaP prostate cancer cells and acts as a positive regulator
of the expression of the oncogenic protein FASN. KLF5 can
also enhance the activity of SREBP. Both KLF5 and SREBP
are increased by androgen treatment and their synergistic action
results in much higher induction of FASN than other SREBP target
genes, such as ACACA, ACLY and other cholesterogenic genes.
Previous reports have demonstrated that the enzymes engaged
in fatty acid synthesis and cholesterol synthesis are up-regulated in
prostate cancer cells by androgen [4,40,41] and SREBPs are
involved in this regulation [17,18,42]. Lipogenic enzymes are re-
ported to be up-regulated by androgen treatment through an
increase in mature SREBP levels [17], and this increased
processing of SREBPs is performed by an escort protein called
SCAP, which is a direct target of the AR [42].
In the present study, FASN was most prominently increased
by androgen treatment in LNCaP prostate cancer cells, and its
up-regulation occurred at the transcriptional level (Figure 1A).
This is in contrast with HER2 (human epidermal growth factor
receptor protein 2)-mediated increases in ACACA and FASN in
breast cancer cells, which takes place at the translational level
by activation of the mTOR (mammalian target of rapamycin)
signalling pathway [43]. However, it was difficult to detect the in-
crease in mature SREBP-1 and SREBP-2 in comparison with the
prominent increase in FASN expression. Furthermore, mRNA and
protein levels of SCAP, known to be a direct target of the AR [42],
were increased minimally by androgen treatment. These results
suggest the possibility that other androgen-regulated transcription
factor(s) might participate and/or assist in regulating FASN levels
in concert with SREBPs in prostate cancer cells, and that KLF5
might be the most promising candidate.
The KLF family of proteins are transcription factors controlling
cell proliferation, differentiation and development [44,45].
Although most KLF family members have not been characterized
for their cellular function, it has been revealed previously that
several KLF members are linked to the control of proliferation and
apoptosis in cancer cells [27,28,37,46–49]. Among these, KLF4
and KLF5 are two closely related members of the zinc-finger-
containing KLFs. Although they bind to a similar DNA sequence
that has either CACCC homology or is G/C-rich, previous re-
ports have demonstrated that they have opposing effects on the
transcription of target genes [50], such as KLF4 [38], TAGLN
[transgelin; also known as SM22α (smooth muscle 22α) [51]
and CYP1A1 (cytochrome P450 1A1) [52]. The differences in the
biochemical behaviour of KLF4 and KLF5 reflects their biological
behaviour. For example, the cellular distribution of the two KLFs
is different from each other. KLF4 is mainly expressed in the post-
mitotic differentiated villus of epithelial cells of the intestinal tract
[53], whereas KLF5 is expressed mostly in proliferating crypt
cells [54]. KLF4 is mainly associated with a process of growth
arrest [53], whereas KLF5 mainly accompanies cell proliferation
[27]. Moreover, forced expression of KLF4 leads to a G1/S-phase
cell-cycle arrest [47], but that of KLF5 causes a transformed
phenotype [27].
In the present study, KLF4 and KLF5 were shown to be
increased by androgen treatment. Promoters for ACACA-PI,
ACACA-PII, ACLY and HMGCS1 contain either none or very
few CACCC consensus sequences for KLF binding, but the FASN
promoter contains multiple CACCC elements throughout the pro-
moter and intron 1 region. In the transient transfection assay,
KLF5, but not KLF4, increased the promoter activity of FASN,
but the other promoters were not affected by KLF5. When
the cells were cultured in 1% CT-FBS-containing medium, the
endogenous levels of KLF5 and FASN were very low. However,
when exogenous KLF5 DNA was introduced by transfection,
the endogenous level of FASN protein increased significantly. In
contrast, the inhibition of KLF5 by siRNA was accompanied by
the down-regulation of FASN. Furthermore, CACCC elements,
scattered throughout the FASN proximal promoter and intron
1 region, were proven to act as response elements for KLF5
to induce FASN promoter activity. Taken together, these results
indicate that among the lipogenic enzymes regulated by androgen
through SREBPs, FASN is the only gene that is regulated by
KLF5.
KLF5 showed synergism with SREBP in the regulation of
FASN expression. In the transient transfection assay, increased
FASN promoter activity by SREBP was strongly up-regulated by
the addition of KLF5. Moreover, SREBP and KLF5 physically
interacted with each other. The synergism between SREBP and
KLF5 implies that small changes in these transcription factors
could drastically change the expression of FASN, which acts
as an important oncogenic protein in cancer cell growth and
proliferation. The molecular target of the KLF5/FASN pathway
revealed in the present study requires further investigation
for the potential development of diagnostic and/or therapeutic
approaches cancer treatment.
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